CBT-501 (Programmable Death-1)

  • A novel IgG4 humanized monoclonal antibody against the Programmable Death-1 (PD-1) membrane receptor on immune cells.
  • Comparable efficacy profile in in-vitro and in-vivo studies to the marketed anti PD-1 antibodies, nivolumab and pembrolizumab, and has a favorable profile in with very low undesirable antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) activity.
  • Under evaluation in two single agent Phase 1 studies designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with advanced solid tumors, recurrent or refractory to standard of care therapies. The trials also aim to determine any dose limiting toxicities or biologically relevant dose and establish a recommended Phase 2 dose for future clinical combination studies.
  • CBT Pharmaceuticals retains worldwide rights while in China, rights were granted to Genor BioPharma, China (a Walvax company).